MedTrace Logo

5 Alpha Reductase Inhibitors And The Risk Of Suicide And Depression

NCT02876757 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 186394

Last updated 2024-01-12

Study results available
· View outcomes & findings →

Summary

In December 2015, Health Canada issued a warning about a potential relationship between suicide and finasteride use and called for further research. No population based studies have assessed the risk of suicide with finasteride use, and this risk is not currently part of the product monograph. Furthermore, the link between depression and finasteride has not been well studied in the older population who are the primary users of this medication.

Conditions

Interventions

DRUG

5ARI

Exposure to finasteride/dutasteride

Sponsors & Collaborators

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Eligibility

Min Age
66 Years
Max Age
120 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2013-12-31
Completion
2017-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02876757 on ClinicalTrials.gov